C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors.

After a minimum 7-day washout period following the [14C]LY2603618 dose, patients will be allowed to continue to receive continued access to LY2603618 in combination with pemetrexed or gemcitabine as outpatients.

Condition or disease	Intervention/treatment	Phase
Advanced Cancer	Drug: LY2603618; Drug: Pemetrexed; Drug: Gemcitabine	Phase 1

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	12 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Disposition of [14C]LY2603618 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumors
Study Start Date :	February 2011
Actual Primary Completion Date :	December 2011
Actual Study Completion Date :	February 2012

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm

Intervention/treatment

Experimental: LY2603618; Single 250 mg intravenous dose of LY2603618 containing [14C] LY2603618. After the completion of a minimum 7 day wash out period, patients may receive additional doses of LY2603618 in combination as follows: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 with 230 mg LY2603618 being administered on days 2, 9 and 16 of a 28-day cycle OR; Pemetrexed 500 mg/m2 on day 1 and 275 mg LY2603618 on day 2 of a 21-day cycle Patients will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression.

Drug: LY2603618; Administered intravenously Drug: Pemetrexed; Administered intravenously; Other Names: LY231514; Alimta Drug: Gemcitabine; Administered intravenously; Other Names: LY188011; Gemzar

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Urinary and fecal excretion of LY2603618 radioactivity over time expressed as a percentage of the total radioactive dose administered [ Time Frame: 7 days ]

Secondary Outcome Measures :

1. Plasma pharmacokinetics of LY2603618 and radioactivity (Cmax) [ Time Frame: 7 days ]
2. Plasma pharmacokinetics of LY2603618 and radioactivity AUC(0-infinity) [ Time Frame: 7 days ]
3. Plasma pharmacokinetics of LY2603618 and radioactivity AUC(0-Tlast) [ Time Frame: 7 days ]
4. Relative abundance of LY2603618 and the metabolites of LY2603618 in urine, and feces [ Time Frame: 7 days ]
5. The number of participants with a tumor response [ Time Frame: Baseline to study completion ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Have a histological or cytological diagnosis of cancer (solid tumor), with clinical or radiologic evidence of locally advanced and/or metastatic disease, for which no life-prolonging therapy exists (that is, refractory to standard therapy and/or therapies known to provide clinical benefit, or for which no standard therapy exists) Note: Patients who have had progressive disease after receiving pemetrexed for metastatic disease are excluded from receiving the combination with pemetrexed during the safety extension study. Patients who have had progressive disease after receiving gemcitabine for metastatic disease are excluded from receiving the combination with gemcitabine during the safety extension study.
• Have a body surface area greater than or equal to 1.37 m^2
• Have given written informed consent prior to any study-specific procedures
• Adequate hematologic, hepatic and renal function
• Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale
• Have discontinued all previous treatments for cancer, including chemotherapy, radiotherapy, anticancer hormone therapy, or other investigational therapy for at least 30 days prior to study entry and recovered from the acute effects of therapy (at least 42 days for mitomycin-C or nitrosoureas, or 60 days for monoclonal antibodies)
• Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedure
• Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and following the last dose of study drug until, in the judgment of the investigator, it is safe for the patient to become pregnant or father a child
• Females with childbearing potential: Have had a negative serum pregnancy test less than or equal to 7 days before the first dose of study drug and must also not be breastfeeding
• Have an estimated life expectancy that, in the judgment of the investigator, will permit the patient to complete 1 full cycle of treatment (beyond the initial [14C]LY2603618 dose)
• Prior radiation therapy for treatment of cancer other than pancreatic is allowed to <25% of the bone marrow and patients must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study entry.

Exclusion Criteria:

• Have received treatment within 28 days of the initial dose of study drug with an experimental agent for noncancer indications that has not received regulatory approval for any indication
• Have previously completed or withdrawn from this study or any other study investigating LY2603618 or any other checkpoint kinase one (Chk1) inhibitor
• Have a known allergy to gemcitabine, pemetrexed, LY2603618, or any ingredient of gemcitabine, pemetrexed, or LY2603618 (like Captisol)
• Have serious preexisting medical conditions (left to the discretion of the investigator) other than advanced cancer
• Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required). Patients with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids and/or anticonvulsants, and their disease is asymptomatic and radiographically stable for at least 90 days
• Have current hematologic malignancies or either acute or chronic leukemia
• Have an active fungal, bacterial, and/or known viral infection including HIV or viral (A, B, or C) hepatitis (screening is not required)
• Have a QTc interval of >500 msec on the screening electrocardiogram (ECG)
• Have electrocardiogram (ECG) abnormalities on the screening ECG such as significant conduction abnormalities, ischemic changes (such as prior Q-wave myocardial infarction and/or marked ischemic ST- and T-wave), arrhythmias (such as persistent or paroxysmal ventricular or supraventricular arrhythmias, including atrial fibrillation), or other ECG abnormalities that would put the patient at unnecessary risk in the opinion of the investigator
• Have participated in a 14C study within the last 6 months prior to screening for this study. The total exposure from this study and the previous study must be less than 5 mSv.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Switzerland
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bruderholz, Switzerland, 4101

Sponsors and Collaborators

Eli Lilly and Company

Investigators

Study Director:	Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time (UTC/GMT- 5 hours, EST)	Eli Lilly and Company

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Eli Lilly and Company
ClinicalTrials.gov Identifier:	NCT01296568 History of Changes
Other Study ID Numbers:	13525; I2I-MC-JMMH ( Other Identifier: Eli Lilly and Company )
First Posted:	February 15, 2011
Last Update Posted:	April 27, 2012
Last Verified:	April 2012

Keywords provided by Eli Lilly and Company:

metastatic solid tumors; Malignant/M-Neoplasm; Pancreas NOS; Absorption; Distribution	Metabolism; Excretion; Mass balance; Metabolic profile; Radiolabeled study

Additional relevant MeSH terms:

Gemcitabine; Pemetrexed; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antiviral Agents	Anti-Infective Agents; Enzyme Inhibitors; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Folic Acid Antagonists; Nucleic Acid Synthesis Inhibitors